Northwestern University Human Resources

Administering a costimulatory antibody 4 days after mRNA vaccination enhances immune responses and vaccine efficacy in mice, suggesting a strategy to improve mRNA vaccines for HIV, coronaviruses, and cancer.

Dakota Wealth Management bought 20,944 Tempus AI shares ($1,185,000) in Q3. Other investors also adjusted stakes. Analysts rate Tempus AI 'Moderate Buy' with a $48.67 target. TEM stock opened at $43.51, with a 1-year range of $22.89-$77.00. Tempus AI reported $165.97M revenue, missing EPS estimates by $2.36.

Upadacitinib (Rinvoq) demonstrated a favorable long-term benefit-risk profile through 76 weeks in adolescents with moderate to severe atopic dermatitis, achieving EASI-75 in 84-96% of patients across three phase III trials. Both 15 mg and 30 mg doses met primary endpoints, with acne and nausea as most common adverse events. Long-term outcomes were consistent with known AE profile, with no new signals observed. The analysis involved 542 adolescents, with data gathered from August 2018 to April 2022.

The TRUST-II trial (NCT04919811) evaluated taletrectinib (AB-106) in ROS1-positive NSCLC patients, showing an 85.2% confirmed overall response rate (cORR) in TKI-naive patients and 61.7% in previously treated patients. The drug demonstrated high intracranial response rates and was generally well-tolerated, with efficacy noted in difficult-to-treat ROS1 translocations.

Upadacitinib (15 mg or 30 mg) with or without topical corticosteroids effectively treats moderate to severe atopic dermatitis in adolescents, maintaining responses through 76 weeks with no new risks observed. This favorable long-term benefit-risk profile is supported by data from 3 large, global phase 3 randomized clinical trials involving 542 adolescents.

Researchers developed a naloxone implant, Naloximeter, that detects opioid overdose and administers naloxone automatically, potentially saving lives without human intervention.

Researchers developed an implant, Naloximeter, that detects opioid overdose and administers naloxone automatically, sending emergency alerts. The device, implanted in animals, successfully reversed overdoses, with potential for broader medical applications.

Kidney Compass, hosted by Brendon Neuen and Shikha Wadhwani, aims to simplify nephrology and clinical trials. The inaugural episode discusses their backgrounds, motivations, and key topics like glomerular disease and diabetic kidney disease. Future episodes will explore deeper aspects of nephrology research.

Oluwatobiloba Oguntoyinbo, a Patient Advocate and Clinical Research Professional, founded Synced Cancer to provide resources for cancer patients. Breast cancer clinical trials are crucial for advancing treatments, but disparities exist, particularly in minority participation. Benefits of trial participation include access to cutting-edge treatments, comprehensive care, and financial support. Barriers to participation include lack of awareness, trust issues, and socioeconomic factors. Patients can access trials through healthcare providers, online platforms, and advocacy groups. Nigeria currently has 5 active breast cancer trials, focusing on risk factors, financial navigation, and mobile health diagnostics.

Northwestern University scientists developed flexible nano-ribbons using peptides and plastic segments, enabling energy storage and digital info recording. These biocompatible, sustainable materials could lead to ultralight electronics and smart fabrics, reducing environmental impact.